Replies to post #7381 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Thanks for posting that. It's absurd that this issue of patent protection remains a topic quarter after quarter. If Helen can pick up the pace with new deals, the patent fall-off would be less of a worrisome matter. Merck has other plans it seems, so we're not going to be partnering with them going forward, I'd wager.
I wonder about the divergence in price targes between JMP, now at $62 and JPM, now at $52. That's a large spread.